Elizabeth J Shpall

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9070926/publications.pdf

Version: 2024-02-01

287 papers	9,455 citations	57631 44 h-index	49773 87 g-index
292 all docs	292 docs citations	292 times ranked	11981 citing authors

#	Article	IF	Citations
1	Chimeric antigen receptor T-cell therapy â€" assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	12.5	1,659
2	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	13.9	1,252
3	Engineering Natural Killer Cells for Cancer Immunotherapy. Molecular Therapy, 2017, 25, 1769-1781.	3.7	337
4	Mesenchymal stem cell-derived exosomes for clinical use. Bone Marrow Transplantation, 2019, 54, 789-792.	1.3	324
5	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigenâ€"Matched Unrelated and Related Donors. Biology of Blood and Marrow Transplantation, 2014, 20, 1975-1981.	2.0	207
6	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	12.5	178
7	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. British Journal of Haematology, 2017, 177, 457-466.	1.2	158
8	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
9	Allogeneic BK Virusâ€"Specific T Cells for Progressive Multifocal Leukoencephalopathy. New England Journal of Medicine, 2018, 379, 1443-1451.	13.9	130
10	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196.	2.0	121
11	Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. Journal of Allergy and Clinical Immunology, 2016, 137, 1498-1505.e1.	1.5	117
12	Targeting the Î±v integrin/TGF-Î² axis improves natural killer cell function against glioblastoma stem cells. Journal of Clinical Investigation, 2021, 131, .	3.9	117
13	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	12.5	114
14	Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 1290-1298.	2.0	113
15	Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT). Blood, 2010, 116, 829-829.	0.6	98
16	CMV-specific T cells generated from naÃ¯ve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine, 2015, 7, 285ra63.	5.8	93
17	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunology Research, 2019, 7, 1267-1279.	1.6	92
18	New and emerging therapies for acute and chronic graftversushost disease. Therapeutic Advances in Hematology, 2018, 9, 21-46.	1.1	90

#	Article	IF	Citations
19	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2018, 24, 1322-1340.	2.0	85
20	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
21	IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood, 2016, 128, 1346-1361.	0.6	81
22	Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Medicine, 2017, 9, 21.	3.6	80
23	A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy, 2016, 18, 985-994.	0.3	77
24	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Translational Medicine, 2014, 3, 1435-1443.	1.6	75
25	Results of a 2â€arm, phase 2 clinical trial using postâ€transplantation cyclophosphamide for the prevention of graftâ€versusâ€host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer, 2016, 122, 3316-3326.	2.0	75
26	Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Bloodâ€"Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clinical Cancer Research, 2021, 27, 3744-3756.	3.2	69
27	Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITDâ€"Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1218-1226.	2.0	66
28	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 1232-1236.	2.0	64
29	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse ofÂAcute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 1948-1954.	2.0	63
30	Utility of the Enzyme-Linked Immunospot Interferon-Î³â€"Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. Journal of Infectious Diseases, 2016, 213, 1701-1707.	1.9	63
31	Postâ€transplantation cyclophosphamide versus conventional graftâ€versusâ€host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology, 2016, 173, 444-455.	1.2	61
32	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 1514-1520.	2.0	61
33	Ex vivo fucosylation of third-party human regulatory T cells enhances antiâ€"graft-versus-host disease potency in vivo. Blood, 2015, 125, 1502-1506.	0.6	59
34	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forÂPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 47-53.	2.0	58
35	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Research, 2018, 28, 432-447.	2.4	58
36	Cord Blood as a Source of Natural Killer Cells. Frontiers in Medicine, 2015, 2, 93.	1.2	56

#	Article	IF	Citations
37	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 319-326.	0.2	55
38	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood, 2016, 128, 297-312.	0.6	54
39	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica, 2017, 102, 110-117.	1.7	54
40	Third-party umbilical cord bloodâ€“derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy, 2014, 16, 90-100.	0.3	53
41	The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 898-907.	1.9	52
42	General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1284-1290.	2.0	51
43	Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Frontiers in Medicine, 2015, 2, 89.	1.2	50
44	Double epigenetic modulation of highâ€dose chemotherapy with azacitidine and vorinostat for patients with refractory or poorâ€risk relapsed lymphoma. Cancer, 2016, 122, 2680-2688.	2.0	48
45	Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro-Oncology, 2020, 22, 1214-1225.	0.6	48
46	Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS ONE, 2015, 10, e0139851.	1.1	47
47	Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1618-1625.	2.0	46
48	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation, 2015, 21, 1914-1920.	2.0	46
49	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Frontiers in Oncology, 2020, 10, 1594.	1.3	46
50	Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clinical Infectious Diseases, 2021, 73, 1346-1354.	2.9	43
51	Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia, 2022, 36, 155-164.	3.3	43
52	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy, 2014, 16, 84-89.	0.3	42
53	A robust, good manufacturing practiceâ€“compliant, clinical-scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy, 2016, 18, 1312-1324.	0.3	39
54	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. American Journal of Hematology, 2017, 92, 331-337.	2.0	39

#	Article	IF	Citations
55	Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood. Molecular Therapy - Methods and Clinical Development, 2017, 5, 13-21.	1.8	38
56	Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Frontiers in Immunology, 2017, 8, 1937.	2.2	38
57	Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. Antiviral Research, 2016, 134, 58-62.	1.9	37
58	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 906-912.	2.0	35
59	A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood, 2017, 129, 740-758.	0.6	35
60	Increasing Chimerism after Allogeneic Stem Cell Transplantation Is Associated with Longer Survival Time. Biology of Blood and Marrow Transplantation, 2014, 20, 1139-1144.	2.0	34
61	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 2166-2171.	2.0	34
62	Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Scientific Reports, 2016, 6, 21757.	1.6	33
63	Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica, 2018, 103, 810-821.	1.7	33
64	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica, 2015, 100, 1361-1370.	1.7	32
65	Leukemia cell mobilization with G-CSF plus plerixafor during busulfanâ€“fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation, 2015, 50, 939-946.	1.3	32
66	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Journal of Clinical Oncology, 2021, 39, 2710-2719.	0.8	32
67	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology, 2021, 18, 435-453.	12.5	31
68	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research, 2020, 26, 3565-3577.	3.2	30
69	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood, 2018, 132, 971-971.	0.6	29
70	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood, 2016, 128, 2819-2823.	0.6	28
71	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer, 2016, 122, 3831-3837.	2.0	27
72	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Advances, 2019, 3, 2057-2068.	2.5	27

#	Article	IF	Citations
73	Large-scale GMP-compliant CRISPR-Cas9â€“mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Advances, 2020, 4, 3357-3367.	2.5	27
74	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology,the, 2022, 9, e350-e360.	2.2	26
75	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biology of Blood and Marrow Transplantation, 2017, 23, 285-292.	2.0	24
76	Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplantation and Cellular Therapy, 2021, 27, 930.e1-930.e10.	0.6	24
77	Generation of glucocorticoid-resistant SARS-CoV-2 TÂcells for adoptive cell therapy. Cell Reports, 2021, 36, 109432.	2.9	24
78	Induction of T-Cell Responses against Cutaneous T-Cell Lymphomas Ex Vivo by Autologous Dendritic Cells Transfected with Amplified Tumor mRNA. Journal of Investigative Dermatology, 2008, 128, 2631-2639.	0.3	23
79	Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer, 2018, 124, 2534-2540.	2.0	23
80	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematology,the, 2018, 5, e532-e542.	2.2	23
81	The CXCR4â€“STAT3â€“IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Frontiers in Immunology, 2017, 8, 1773.	2.2	23
82	A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Advances, 2019, 3, 4117-4130.	2.5	23
83	Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clinical Cancer Research, 2019, 25, 2610-2620.	3.2	23
84	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1405-1412.	2.0	22
85	Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Molecular Imaging and Biology, 2016, 18, 838-848.	1.3	22
86	Ex Vivo Mesenchymal Precursor Cellâ€“Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biology of Blood and Marrow Transplantation, 2017, 23, 1359-1366.	2.0	22
87	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e1-e5.	0.2	21
88	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 665-671.	2.0	21
89	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Frontiers in Immunology, 2021, 12, 626098.	2.2	21
90	Engineering cord blood to improve engraftment after cord blood transplant. Stem Cell Investigation, 2017, 4, 41-41.	1.3	20

#	Article	IF	Citations
91	Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem CellÂTransplantation for Relapsed and Refractory HodgkinÂLymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1333-1337.	2.0	19
92	Chimeric antigen receptor Tâ€cell therapy toxicities. British Journal of Clinical Pharmacology, 2021, 87, 2414-2424.	1.1	19
93	High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 675679.	2.2	19
94	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia, 2022, 36, 257-262.	3.3	19
95	Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells.. Blood, 2006, 108, 3654-3654.	0.6	19
96	Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-Î²-p38-ALDH2 pathway. PLoS ONE, 2020, 15, e0242809.	1.1	19
97	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplantation, 2022, 57, 51-56.	1.3	19
98	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. European Journal of Haematology, 2017, 99, 532-535.	1.1	18
99	Poor immune reconstitution is associated with symptomatic <scp>BK</scp> polyomavirus viruria in allogeneic stem cell transplant recipients. Transplant Infectious Disease, 2017, 19, e12632.	0.7	18
100	HIV-Specific T Cells Generated from Naive T Cells Suppress HIV InÂVitro and Recognize Wide Epitope Breadths. Molecular Therapy, 2018, 26, 1435-1446.	3.7	18
101	CARs in Chronic Lymphocytic Leukemia â€“ Ready to Drive. Current Hematologic Malignancy Reports, 2013, 8, 60-70.	1.2	17
102	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2016, 57, 1607-1615.	0.6	17
103	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 1439-1445.	2.0	17
104	Significance of minimal residual disease monitoring by realâ€time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer, 2020, 126, 2183-2192.	2.0	17
105	Long-Term Outcomes after Treatment with Clofarabineâ€‰Â±â€‰Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2016, 22, 1792-1800.	2.0	16
106	Role of MSC-derived galectin 3 in the AML microenvironment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 959-969.	1.9	16
107	Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Frontiers in Immunology, 2018, 9, 2444.	2.2	16
108	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 197-203.	2.0	16

#	Article	IF	Citations
109	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 5579-5587.	3.2	16
110	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
111	Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. Journal of Visualized Experiments, 2015, , .	0.2	15
112	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation, 2016, 22, 961-965.	2.0	15
113	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 1602-1609.	2.0	15
114	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1146-1154.	0.4	15
115	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 505-514.	2.0	15
116	Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma. Haematologica, 2022, 107, 1555-1566.	1.7	15
117	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer, 2017, 123, 2661-2670.	2.0	14
118	Prognostic Index for Critically Ill Allogeneic Transplantation Patients. Biology of Blood and Marrow Transplantation, 2017, 23, 991-996.	2.0	14
119	Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: The automated Sepax system versus the manual Ficoll method. Cytotherapy, 2017, 19, 433-439.	0.3	14
120	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 2021, 27, 689-695.	0.6	14
121	Novel Cord Blood Transplant Therapies. Biology of Blood and Marrow Transplantation, 2011, 17, S39-S45.	2.0	13
122	Impact of the timing of hepatitis B virus identification and antiâ€“hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer, 2017, 123, 3367-3376.	2.0	13
123	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy, 2017, 19, 272-284.	0.3	13
124	Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy, 2018, 20, 1089-1101.	0.3	13
125	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research in Translational Medicine, 2019, 67, 51-55.	1.2	13
126	Endovascular Selective Intra-Arterial Infusion of Mesenchymal Stem Cells Loaded With Delta-24 in a Canine Model. Neurosurgery, 2021, 88, E102-E113.	0.6	13

#	Article	IF	Citations
127	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica, 2021, 106, 3211-3214.	1.7	13
128	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Seminars in Oncology Nursing, 2021, 37, 151216.	0.7	13
129	Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12.	6.9	13
130	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 272.e1-272.e5.	0.6	12
131	Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Frontiers in Immunology, 2021, 12, 631353.	2.2	12
132	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer, 2017, 123, 3568-3575.	2.0	11
133	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2019, 25, 1039-1044.	2.0	11
134	Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRAS^{G12D}siRNA in patients with metastatic pancreatic cancer harboring a KRAS^{G12D} mutation.. Journal of Clinical Oncology, 2022, 40, TPS633-TPS633.	0.8	11
135	Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy, 2014, 16, 1153-1157.	0.3	10
136	Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplantation, 2019, 54, 1245-1253.	1.3	10
137	RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neuro-Oncology Advances, 2020, 2, vdaa132.	0.4	10
138	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 1003.e1-1003.e13.	0.6	10
139	First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood, 2013, 122, 166-166.	0.6	10
140	PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy, 2016, 18, 995-1001.	0.3	9
141	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biology of Blood and Marrow Transplantation, 2020, 26, 1759-1769.	2.0	9
142	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer, 2021, 127, 1598-1605.	2.0	9
143	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood, 2022, 139, 1289-1301.	0.6	9
144	Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e105-e109.	0.2	8

#	Article	IF	Citations
145	Treg adoptive therapy: is more better?. Blood, 2016, 127, 962-963.	0.6	8
146	Migratory Pulmonary Infiltrates in a Patient With COVID-19 Infection and the Role of Corticosteroids. Mayo Clinic Proceedings, 2020, 95, 2038-2040.	1.4	8
147	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leukemia and Lymphoma, 2022, 63, 710-721.	0.6	8
148	Non-fucosylated CB CD34+ cells represent a good target for enforced fucosylation to improve engraftment following cord blood transplantation. Cytotherapy, 2017, 19, 285-292.	0.3	7
149	Longâ€term followâ€up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed Tâ€cell chimerism is associated with high relapse risk and inferior survival. British Journal of Haematology, 2017, 177, 567-577.	1.2	7
150	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1340-1346.	2.0	7
151	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Advances, 2020, 4, 1296-1306.	2.5	7
152	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Frontiers in Oncology, 2021, 11, 625707.	1.3	7
153	Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. Blood, 2015, 126, 1737-1737.	0.6	7
154	T Cells Demonstrate Enhanced Specificity for CD19+ Malignancies When Stimulated with IL-21.. Blood, 2008, 112, 1539-1539.	0.6	7
155	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Frontiers in Oncology, 2021, 11, 800110.	1.3	7
156	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation, 2022, 57, 1142-1149.	1.3	7
157	Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations. Cytotherapy, 2015, 17, 418-427.	0.3	6
158	Haploidentical transplants for patients with relapse after the first allograft. American Journal of Hematology, 2020, 95, 1187.	2.0	6
159	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy, 2021, 27, 913.e1-913.e12.	0.6	6
160	Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica, 2021, , .	1.7	6
161	Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure.. Blood, 2006, 108, 312-312.	0.6	6
162	Enrichment of Mononuclear Cells From Cryopreserved Cord Blood Units Using the Purecellâ€•Select System.. Blood, 2009, 114, 2159-2159.	0.6	6

#	Article	IF	Citations
163	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. Blood, 2016, 128, 2270-2270.	0.6	6
164	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2022, 28, 395.e1-395.e11.	0.6	6
165	Primary mediastinal large Bâ€cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. British Journal of Haematology, 2020, 190, e114-e117.	1.2	5
166	Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells. Journal of Neurosurgery, 2020, 133, 1182-1190.	0.9	5
167	Haploidentical transplants for patients with graft failure after the first allograft. American Journal of Hematology, 2020, 95, E267.	2.0	5
168	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 1746-1749.	1.3	5
169	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood, 2012, 120, 4200-4200.	0.6	5
170	Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). Blood, 2013, 122, 410-410.	0.6	5
171	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood, 2015, 126, 854-854.	0.6	5
172	TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Communications Biology, 2022, 5, 167.	2.0	5
173	All-in-one processing of heterogeneous human cell grafts for gene and cell therapy. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16012.	1.8	4
174	IV Busulfan (Bu) with Fludarabine (Flu) or Cyclophosphamide (Cy) - Comparing Ablative Conditioning Regimens for Allogeneic Transplantation in AML/MDS.. Blood, 2004, 104, 97-97.	0.6	4
175	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. Blood, 2016, 128, 3554-3554.	0.6	4
176	Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Molecular Diagnostics, 2016, 18, 638-642.	1.2	3
177	Graft loss attributed to possible transfusionâ€transmitted ehrlichiosis following cord blood stem cell transplant. Transplant Infectious Disease, 2018, 20, e12899.	0.7	3
178	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 404.e1-404.e5.	0.6	3
179	Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells.. Blood, 2008, 112, 2333-2333.	0.6	3
180	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfanâ€‰Â±â€‰clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	3

#	Article	IF	Citations
181	Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S18-S22.	0.2	2
182	Characterizing human herpes virus 6 following hematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice, 2015, 21, 85-92.	0.5	2
183	Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta Haematologica, 2019, 142, 176-184.	0.7	2
184	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica, 2021, 144, 74-81.	0.7	2
185	Postâ€transplantation donorâ€derived Sezary syndrome in a patient with <scp>A91V PRF1</scp> variant hemophagocytic lymphohistiocytosis. American Journal of Hematology, 2021, 96, E350-E353.	2.0	2
186	Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy, 2021, 23, 1029-1035.	0.3	2
187	Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.. Blood, 2005, 106, 660-660.	0.6	2
188	Lenalidomide Treatment Enhances Immunological Synapse Formation of Cord Blood Natural Killer Cells with B Cells Derived From Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1794-1794.	0.6	2
189	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4321-4321.	0.6	2
190	Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.. Journal of Clinical Oncology, 2014, 32, 8508-8508.	0.8	2
191	Phase II study of umbilical cord bloodâ€“derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. Journal of Clinical Oncology, 2022, 40, 8009-8009.	0.8	2
192	Nasal Microbiota Changes are Associated with Progression to Lower Respiratory Infection Following Respiratory Syncytial Virus Upper Respiratory Infection in Hematopoietic Cell Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
193	Prolonged neurotoxicity in a lymphoma patient after CD19â€directed CAR Tâ€cell therapy: A case report and brief review of the literature. Advances in Cell and Gene Therapy, 2021, 4, e104.	0.6	1
194	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	0.6	1
195	Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.. Blood, 2004, 104, 734-734.	0.6	1
196	HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT).. Blood, 2006, 108, 3125-3125.	0.6	1
197	Monoculture-Derived T Lymphocytes Providing Multiple Virus Specificity and Anti-Leukemia Activity for Recipients of Hematopietic Stem Cells or Umbilical Cord Blood Transplants. Blood, 2008, 112, 3909-3909.	0.6	1
198	Dramatic Reduction of Chronic Lymphocytic Leukemia (CLL) Cells Following Adoptive Transfer of Cord Blood (CB) Natural Killer (NK) Cells Using CB-Engrafted NOD-SCID IL2RÎ³null (NSG) Mice as a Model.. Blood, 2009, 114, 2370-2370.	0.6	1

#	Article	IF	Citations
199	CD137L Reverse the Immunological Synapse Defects of Natural Killer Cells in Acute Myeloid Leukemia. Blood, 2011, 118, 246-246.	0.6	1
200	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. Blood, 2012, 120, 3094-3094.	0.6	1
201	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood, 2013, 122, 3048-3048.	0.6	1
202	Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood, 2013, 122, 305-305.	0.6	1
203	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5884-5884.	0.6	1
204	Double Loading of Dendritic Cell MHC Class I and MHC Class II with an AML Antigen Repertoire Enhances Primary and Secondary T-Cell Responses In Vitro.. Blood, 2004, 104, 2529-2529.	0.6	1
205	Acute Myeloid Leukemia Lysate Loaded Dendritic Cells Exhibit Significant Phagocytic Function and Elicit Antigen-Specific Immune Response.. Blood, 2004, 104, 2527-2527.	0.6	1
206	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. Blood, 2005, 106, 2923-2923.	0.6	1
207	Cell-Autonomous Upregulation of Dendritic Cell Immunocompetence Is Antigen-Dependent.. Blood, 2005, 106, 2230-2230.	0.6	1
208	Superior Acute Myeloid Leukemia-Specific T Cell Responses Using Dendritic Cells Pulsed with Apoptotic Bodies, vs.Tumor Lysates or mRNA.. Blood, 2005, 106, 295-295.	0.6	1
209	Optimizing Immunotherapy in Multiple Myeloma: Restoring the Function of Patientâ€™s Monocyte-Derived Dendritic Cells by Inhibiting p38 or Activating MEK/ERK MAPK and Neutralizing Interleukin-6 in the Progenitor Cells.. Blood, 2006, 108, 3701-3701.	0.6	1
210	Donor-Recipient Mismatches in MHC Class I Chain-Related Gene a (MICA) in Unrelated Donor (UD) Transplantation. Blood, 2008, 112, 58-58.	0.6	1
211	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. Blood, 2012, 120, 3129-3129.	0.6	1
212	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	0.6	1
213	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020, 136, 17-18.	0.6	1
214	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood, 2020, 136, 34-35.	0.6	1
215	Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia. Blood, 2020, 136, 11-12.	0.6	1
216	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 24-25.	0.6	1

#	Article	IF	Citations
217	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 307.e1-307.e8.	0.6	1
218	External validation of the <scp>HIGHâ€2â€LOW</scp> model: A predictive score for venous thromboembolism after allogeneic transplant. American Journal of Hematology, 2022, 97, 740-748.	2.0	1
219	Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.. Journal of Clinical Oncology, 2022, 40, 7536-7536.	0.8	1
220	The ability of CMVâ€“specific ELISPOT assay to predict outcome of low level CMV reactivation in hematopoietic cell transplant recipients. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
221	Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transplant Infectious Disease, 2020, 22, e13395.	0.7	0
222	Disturbed Regulation and Activity of PI 3-Kinase Activity Due to Enhanced Lyn Kinase but Decreased Ship-1 and Gab2 Levels in Patients with Myelodysplastic Syndrome.. Blood, 2004, 104, 3423-3423.	0.6	0
223	Retroviral Gene Transfer with Triple Genetic Reporter Genes into Human Cord Blood CD133+ Cells.. Blood, 2004, 104, 5260-5260.	0.6	0
224	A Pilot Study for Haploidentical Transplant Using a Chemotherapy only Preparative Regimen eith T-Cell Depleted Haploidentical Transplant and Intensive Antibiotic Prophylaxis To Treat Advanced Leukemia Patients (pts).. Blood, 2004, 104, 5184-5184.	0.6	0
225	High Efficiency Transduction of Human Mesenchymal Stem Cells Using Retroviral Gene Transfer with Triple Reporter Genes.. Blood, 2004, 104, 4258-4258.	0.6	0
226	Abnormal PI 3-Kinase Activity Due to Increased Lyn with Decreased PTEN and Absent SHIP in Bone Marrow Cells from Patients with Myelodysplastic Syndromes.. Blood, 2005, 106, 3446-3446.	0.6	0
227	In Utero Is Superior to Ex Utero Cord Blood Collection.. Blood, 2006, 108, 3645-3645.	0.6	0
228	Non-Integrating Gene Transfer To Redirect Specificity of Lymphocytes towards Pediatric CD19+ Malignancies. Blood, 2007, 110, 3739-3739.	0.6	0
229	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkinâ€™s Lymphomas (NHLs).. Blood, 2007, 110, 1900-1900.	0.6	0
230	CD117 Expression May Signify Enduring Proliferative Capacity of Amniotic Fluid-Derived Mesenchymal Stem Cells (MSC).. Blood, 2007, 110, 3699-3699.	0.6	0
231	Graft-Versus-Host Disease (GVHD) in Cord Blood Transplantation (CBT): Risk Factors, Clinical Manifestations and Outcomes.. Blood, 2007, 110, 2977-2977.	0.6	0
232	Tacrolimus and Short-Term Methotrexate (mini-MTX) for Graft Versus Host Disease (GVHD) Prophylaxis after Unrelated Single Unit Cord Blood Transplant (CBT) in Pediatric Patients.. Blood, 2007, 110, 5018-5018.	0.6	0
233	Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 3050-3050.	0.6	0
234	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. Blood, 2007, 110, 48-48.	0.6	0

#	Article	IF	Citations
235	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	0.6	0
236	CD19-Specific T Cells for Treatment of Pediatric Acute Lymphocytic Leukemia Using Sleeping Beauty Transposition.. Blood, 2007, 110, 2820-2820.	0.6	0
237	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood, 2007, 110, 5015-5015.	0.6	0
238	Ex Vivo Expansion of Cord Blood Natural Killer Cells Overcomes Impaired Immune Synapse Formation and Effector Function in Acute Myeloid Leukemia. Blood, 2008, 112, 2905-2905.	0.6	0
239	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 4326-4326.	0.6	0
240	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood, 2008, 112, 3297-3297.	0.6	0
241	Impaired Natural Killer Cells Immune Synapse Formation in Acute Myeloid Leukemia.. Blood, 2009, 114, 2663-2663.	0.6	0
242	Ex Vivo IL-2 Expansion of CB-NK Cells Promotes Synergistic LFA-1 and CD2 Engagement at the NK Cell Lytic Immune Synapse; Implications for Adoptive CB-NK Cell Therapy in Acute Myeloid Leukemia.. Blood, 2009, 114, 3029-3029.	0.6	0
243	HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance. Blood, 2010, 116, 1370-1370.	0.6	0
244	Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS.. Blood, 2010, 116, 3446-3446.	0.6	0
245	Targeting Chronic Lymphocytic Leukemia with Cord Blood NK Cells In NSG Model. Blood, 2010, 116, 2453-2453.	0.6	0
246	Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. Blood, 2010, 116, 2100-2100.	0.6	0
247	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood, 2010, 116, 2341-2341.	0.6	0
248	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood, 2011, 118, 3106-3106.	0.6	0
249	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood, 2011, 118, 2006-2006.	0.6	0
250	Reconstitution of Lymphocyte Subsets and Outcomes After Matched and Mismatched Hematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4485-4485.	0.6	0
251	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2013, 31, 7010-7010.	0.8	0
252	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	0.6	0

#	Article	IF	Citations
253	Phosphorylation Of GSK3Î² Is Associated With Inferior Survival In Acute Myeloid Leukemia and Is An Indicator Of AKT Activation In AML Blasts and Bone Marrow Mesenchymal Stem Cells. Blood, 2013, 122, 2551-2551.	0.6	0
254	Is There An Expiration Date For Cord Blood Units In Storage?. Blood, 2013, 122, 299-299.	0.6	0
255	NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes. Blood, 2013, 122, 3487-3487.	0.6	0
256	Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 2880-2880.	0.6	0
257	BK virus as a predictor of chronic kidney disease in hematopoietic stem cell recipients.. Journal of Clinical Oncology, 2014, 32, 7016-7016.	0.8	0
258	Acute Myeloid Leukemia (AML) Cells Alter the Bone Marrow Microenvironment By Inducing Osteogenic and Suppressing Adipogenic Differentiation of MSCs through BMP-RUNX2-CTGF Mediated Mechanisms. Blood, 2015, 126, 2403-2403.	0.6	0
259	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2276-2276.	0.6	0
260	EPCR Guides Hematopoietic Stem Cells Homing to the Bone Marrow Independently of Niche Clearance. Blood, 2016, 128, 4538-4538.	0.6	0
261	Ex-Vivo Fucosylation Improves the Anti-Graft-Versus-Host-Disease Effects of Mesenchymal Stem Cells in the NOD/SCID/IL-2R Null Mouse Model. Blood, 2016, 128, 4559-4559.	0.6	0
262	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Blood, 2018, 132, 4667-4667.	0.6	0
263	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood, 2018, 132, 4607-4607.	0.6	0
264	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Blood, 2019, 134, 3596-3596.	0.6	0
265	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood, 2019, 134, 4598-4598.	0.6	0
266	Next Generation CRISPR Gene-Edited and Off-the-Shelf Virus-Specific T-Cells for the Immunocompromised Patient. Blood, 2019, 134, 1944-1944.	0.6	0
267	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood, 2021, 138, 1802-1802.	0.6	0
268	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 1779-1779.	0.6	0
269	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 3941-3941.	0.6	0
270	Impact of Vitamin D Deficiency on Survival for Patients Received Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT). Blood, 2021, 138, 4853-4853.	0.6	0

#	Article	IF	Citations
271	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 18-19.	0.6	0
272	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	0.6	0
273	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	0.6	0
274	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-21.	0.6	0
275	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. Blood, 2020, 136, 10-11.	0.6	0
276	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood, 2020, 136, 23-24.	0.6	0
277	Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 2020, 136, 23-24.	0.6	0
278	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood, 2020, 136, 40-41.	0.6	0
279	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. Blood, 2020, 136, 39-40.	0.6	0
280	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine Â± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2020, 136, 37-38.	0.6	0
281	Title is missing!. , 2020, 15, e0242809.		0
282	Title is missing!. , 2020, 15, e0242809.		0
283	Title is missing!. , 2020, 15, e0242809.		0
284	Title is missing!. , 2020, 15, e0242809.		0
285	Cord Blood Transplantation. , 0, , 453-461.		0
286	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. Journal of Clinical Oncology, 2022, 40, e20024-e20024.	0.8	0
287	Impact of induction approach on post-stem cell transplant (SCT) outcomes in older adults with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2022, 40, 7038-7038.	0.8	0